Consensus estimates for Q3 2026 place revenue at approximately $5.0 million and earnings per share (EPS) at a loss of $5.55, with the stock trading near $9.81 compared to an average analyst price target of $95.40.
Investors are primarily focused on the potential FDA acceptance of the New Drug Application (NDA) for seralutinib, which would trigger a critical $125 million milestone payment from a recent financing agreement.
The company submitted the NDA in September 2026 despite the Phase 3 PROSERA study narrowly missing its primary statistical threshold. This reporting period also reflects the impact of a 1-for-80 reverse stock split and the reacquisition of full global rights to seralutinib from the Chiesi Group.